{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T10:33:19Z","timestamp":1681295599033},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00108-016-0099-6","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T13:22:46Z","timestamp":1467379366000},"page":"773-783","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HIV-Infektion"],"prefix":"10.1007","volume":"57","author":[{"given":"J. K.","family":"Rockstroh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Wasmuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,1]]},"reference":[{"key":"99_CR1","unstructured":"Deutsche Aids Gesellschaft. www.daignet.de , zugegriffen 15.06.2016"},{"key":"99_CR2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"JD Lundgren","year":"2015","unstructured":"INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, F\u00e4tkenheuer G et\u00a0al (2015) Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373:795\u2013807","journal-title":"N Engl J Med"},{"key":"99_CR3","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJM198112103052401","volume":"305","author":"MS Gottlieb","year":"1981","unstructured":"Gottlieb MS, Schroff R, Schanker HM et\u00a0al (1981) Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305:1425\u20131431","journal-title":"N Engl J Med"},{"key":"99_CR4","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","volume":"220","author":"F Barre-Sinoussi","year":"1983","unstructured":"Barre-Sinoussi F, Chermann JC, Rey F et al (1983) Isolation of a T\u2011lymphotropic retrovirus from a patient at risk for AIDS. Science 220:868\u2013871","journal-title":"Science"},{"key":"99_CR5","unstructured":"The Joint United Nations Programme on HIV and AIDS. www.unaids.org , zugegriffen: 01.04.2016"},{"key":"99_CR6","unstructured":"Robert Koch Institut - Neue Sch\u00e4tzung zu HIV\/AIDS in Deutschland. https:\/\/www.rki.de\/DE\/Content\/Service\/Presse\/Pressemitteilungen\/2015\/08_2015.html"},{"key":"99_CR7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1468-1293.2010.00857.x","volume":"12","author":"A Antinori","year":"2011","unstructured":"Antinori A, Coenen T, Costagiola D, et al, European Late Presenter Consensus Working Group (2011) Late presentation of HIV infection: a consensus definition. HIV Med 12:61\u201364","journal-title":"HIV Med"},{"key":"99_CR8","doi-asserted-by":"crossref","first-page":"e52845","DOI":"10.1371\/journal.pone.0052845","volume":"8","author":"AK Sullivan","year":"2013","unstructured":"Sullivan AK, Raben D, Reekie J et al (2013) Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). PLoS ONE 8:e52845","journal-title":"PLoS ONE"},{"key":"99_CR9","first-page":"1","volume-title":"HIV 2014\/2015","author":"C Hoffmann","year":"2014","unstructured":"Hoffmann C, Rockstroh JK (2014) HIV 2014\/2015. Medizin Fokusverlag, Hamburg, S\u00a01\u2013846"},{"issue":"Suppl 1","key":"99_CR10","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.jcv.2013.08.009","volume":"58","author":"EO Mitchell","year":"2013","unstructured":"Mitchell EO, Stewart G, Bajzik O et al (2013) Performance comparison of the 4th generation bio-rad laboratories GS HIV combo Ag\/ab EIA on the EVOLIS\u2122 automated system versus abbott ARCHITECT HIV Ag\/ab combo, ortho anti-HIV 1+2 EIA on Vitros ECi and Siemens HIV-1\/O\/2 enhanced on Advia centaur. J Clin Virol 58(Suppl 1):e79\u2013e84","journal-title":"J Clin Virol"},{"key":"99_CR11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000332015","volume":"55(2","author":"M Oette","year":"2012","unstructured":"Oette M, Reuter S, Kaiser R, et al, RESINA Study group (2012) RESINA Study group. Epidemiology of transmitted drugresistance in chronically HIV-infected patients in Germany: the RESINA study 2001\u20132009. Intervirology 55(2:154\u2013159","journal-title":"Intervirology"},{"key":"99_CR12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/ije\/dyr164","volume":"41","author":"C Lewden","year":"2012","unstructured":"The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden C, Bouteloup V, Wit S de et al (2012) All-cause mortality in treated HIV-infected adults with CD4 \u2265500\/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 41:433\u2013445","journal-title":"Int J Epidemiol"},{"key":"99_CR13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","volume":"365","author":"MS Cohen","year":"2011","unstructured":"Cohen MS, Chen YQ, McCauley M et al (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365:493\u2013505","journal-title":"N Engl J Med"},{"key":"99_CR14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1097\/00002030-199813000-00008","volume":"12","author":"JM Raboud","year":"1998","unstructured":"Raboud JM, Montaner JS, Conway B et al (1998) Suppression of plasma viral load below 20 copies\/ml is required to achieve a long-term response to therapy. AIDS 12:1619\u20131624","journal-title":"AIDS"},{"key":"99_CR15","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1097\/00002030-199805000-00001","volume":"12","author":"DJ Kempf","year":"1998","unstructured":"Kempf DJ, Rode RA, Xu Y et al (1998) The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 12:F9\u201314","journal-title":"AIDS"},{"key":"99_CR16","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1086\/378301","volume":"37","author":"AK Sethi","year":"2003","unstructured":"Sethi AK, Celentano DD, Gange SJ et\u00a0al (2003) Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 37:1112\u20131118","journal-title":"Clin Infect Dis"},{"key":"99_CR17","first-page":"RR-17","volume":"41","author":"CDC","year":"1992","unstructured":"CDC (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Cent Dis Control Prev 41:RR-17","journal-title":"Cent Dis Control Prev"},{"key":"99_CR18","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","volume":"346","author":"S Walmsley","year":"2002","unstructured":"Walmsley S, Bernstein B, King M et al (2002) Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346:2039\u20132046","journal-title":"N Engl J Med"},{"key":"99_CR19","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1517\/14656566.2015.1109632","volume":"16","author":"A Capetti","year":"2015","unstructured":"Capetti A, Cossu MV, Rizzardini G (2015) Darunavir\/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance. Expert Opin Pharmacother 16:2689\u20132702","journal-title":"Expert Opin Pharmacother"},{"key":"99_CR20","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"S Walmsley","year":"2013","unstructured":"Walmsley S, Antela A, Clumeck N (2013) Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 369:1807\u20131818","journal-title":"N Engl J Med"},{"key":"99_CR21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2352-3018(15)00027-2","volume":"2","author":"JM Molina","year":"2015","unstructured":"Molina JM, Clotet B, Lunzen J van, et al, FLAMINGO study team (2015) Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV 2:127\u2013136","journal-title":"Lancet HIV"},{"key":"99_CR22","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","volume":"379","author":"PE Sax","year":"2012","unstructured":"Sax PE, DeJesus E, Mills A et al (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48\u00a0weeks. Lancet 379:2439\u20132448","journal-title":"Lancet"},{"key":"99_CR23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","volume":"63","author":"JK Rockstroh","year":"2013","unstructured":"Rockstroh JK, DeJesus E, Lennox JL et al (2013) Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: final 5\u2011year results from STARTMRK. J Acquir Immune Defic Syndr 63:77\u201385","journal-title":"J Acquir Immune Defic Syndr"},{"key":"99_CR24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M14-1084","volume":"161","author":"JL Lennox","year":"2014","unstructured":"Lennox JL, Landovitz RJ, Ribaudo HJ, et al, ACTG A5257 Team (2014) Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 161:461\u2013471","journal-title":"Ann Intern Med"},{"key":"99_CR25","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"S Mallal","year":"2008","unstructured":"Mallal S, Phillips E, Carosi G, et al, PREDICT-1 Study Team (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568\u2013579","journal-title":"N Engl J Med"},{"key":"99_CR26","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/QAD.0000000000000169","volume":"28","author":"C Cohen","year":"2014","unstructured":"Cohen C, Wohl D, Arribas JR et al (2014) 48 results from a randomized clinical trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate vs. efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-na\u00efve HIV-1-infected adults. AIDS 28:989\u2013997","journal-title":"AIDS"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-016-0099-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-016-0099-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-016-0099-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T17:37:05Z","timestamp":1498325825000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-016-0099-6"}},"subtitle":["Test und Behandlung"],"short-title":[],"issued":{"date-parts":[[2016,7,1]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["99"],"URL":"https:\/\/doi.org\/10.1007\/s00108-016-0099-6","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,1]]}}}